)
Daiichi Sankyo Company (4568) investor relations material
Daiichi Sankyo Company Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q1 FY2026 revenue rose 21.1% year-over-year to JPY 574.7 billion, driven by strong sales of ENHERTU and DATROWAY and favorable foreign exchange effects.
Core operating profit increased 6.2% to JPY 107.3 billion, but operating profit fell 12.0% to JPY 85.1 billion due to higher restructuring expenses in the EU Specialty Business Unit and non-core costs.
Profit attributable to owners declined 19.7% to JPY 68.6 billion, mainly due to higher income taxes and financial expenses.
Correction of FY2025 results due to booking errors in accounts payable and SG&A; internal controls reviewed and strengthened.
Total comprehensive income rose 28.5% to JPY 87.7 billion, reflecting positive currency translation differences.
Financial highlights
Q1 FY2026 revenue increased by JPY 100.1 billion year-over-year, with a JPY 41.9 billion positive forex impact.
Core operating profit up JPY 6.3 billion (6.2% YoY) to JPY 107.3 billion; operating profit down JPY 11.6 billion (12.2% YoY) to JPY 85.1 billion.
Profit attributable to owners dropped JPY 16.9 billion YoY to JPY 68.6 billion; EPS down 18.1% to JPY 37.72.
Cost of sales rose 43.9% YoY to JPY 126.0 billion; SG&A up 25.5% to JPY 226.0 billion, mainly from higher profit sharing with AstraZeneca.
R&D expenses grew 9.0% to JPY 115.5 billion, reflecting intensified investment in ADCs and pipeline projects.
Outlook and guidance
FY2026 revenue forecast raised to JPY 2.34 trillion, mainly due to yen depreciation and strong ENHERTU sales.
Operating profit forecast raised to JPY 320 billion, reflecting reversal of Odawara site provision.
Core operating profit guidance unchanged at JPY 360 billion; profit attributable to owners forecast at JPY 251 billion, with EPS revised down to JPY 137.94 due to higher tax rate and SG&A.
Annual dividend forecast increased to JPY 100 per share, up JPY 22 from the prior year.
Forex assumptions: JPY 155/USD, JPY 180/EUR for Q2 onward.
- ADC-based regimens show strong efficacy and safety in multiple cancers, with new biomarkers advancing.4568
WCLC/ESMO 2024 Conference - Oncology-driven revenue and profit growth offset by one-time expenses, with strong future targets.4568
Q4 2026 - Oncology-driven revenue and profit growth, robust outlook, and higher dividend planned.4568
Q3 2026 - Oncology-driven revenue growth offset by higher costs and revised profit guidance.4568
Q2 2026 - T-DXd delivers robust efficacy and safety in HER2-low/ultralow breast cancer, expanding treatment options.4568
Status Update - Multiple new oncology launches and clinical catalysts set to triple eligible patients by 2026.4568
Status Update - ENHERTU® and DXd ADCs drive clinical, regulatory, and supply advances, expanding global impact.4568
Status Update - Oncology and ENHERTU sales drove strong revenue and profit growth, with ongoing market and approval risks.4568
Q1 2025 - Record profit and revenue growth driven by oncology, with higher dividends and buybacks ahead.4568
Q4 2025
Next Daiichi Sankyo Company earnings date
Next Daiichi Sankyo Company earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage